Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes

August 2013

Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes.

This new DPP-4 inhibitor is a "me too"...similar to Januvia (sitagliptin), Onglyza (saxagliptin), and Tradjenta (linagliptin).

Continue to recommend lifestyle changes and metformin first.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote